Rossari Biotech Limited has announced the completion of Ms. Aparna Sharma's tenure as Independent Director on April 28, 2026. The company informed stock exchanges about this corporate governance change under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Tenure Completion

Ms. Aparna Sharma (DIN: 07132341) completed her term as an Independent Director and consequently ceased to hold the position with effect from the end of day on April 28, 2026. The cessation was due to the natural completion of her current term as an Independent Director.

Board Committee Memberships

During her tenure, Ms. Aparna Sharma held significant positions across multiple board committees. She served as Chairperson of the Stakeholders Relationship Committee and was a member of three other key committees.

Ms. Aparna Sharma automatically ceased to be Chairperson and Member of all the aforementioned committees in Rossari Biotech Limited with effect from the end of day on April 28, 2026.

Management Acknowledgment

The Board of Directors and the Management of the Company placed on record their deep appreciation for the contributions made by Ms. Aparna Sharma during her association with the company over the years. The disclosure was made in compliance with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

The company secretary Parul Gupta signed the regulatory filing, ensuring proper compliance with listing obligations and disclosure requirements.

Rossari Biotech Limited has disclosed that its material subsidiary, Unitop Chemicals Private Limited, has approved the sale of office premises in Mumbai for Rs 10 crores. The transaction was approved by the subsidiary's Board of Directors on April 03, 2026, marking a significant asset divestment for the group.

Transaction Details

The subsidiary has agreed to sell its office premises located at Saki Naka, Mumbai at a consideration of approximately Rs 10 crores (Rupees Ten Crore only). The proposed transaction is expected to reach completion by the end of Q2 FY27, providing a clear timeline for the asset disposal.

Operational Impact Assessment

The company has provided assurance regarding the transaction's impact on business operations. As no business operations are currently conducted from the premises proposed to be sold by the subsidiary, the sale will not have any impact on either the company's or subsidiary's business operations. This strategic decision appears to be focused on asset optimization rather than operational restructuring.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30(9) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that the sale of the premises does not constitute the sale of an undertaking within the meaning of Section 180(1)(a) of the Companies Act, 2013.

Additional details required under Regulation 30 of the Listing Regulations, as per SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, will be provided upon execution of the agreement. This ensures full regulatory compliance throughout the transaction process.

Corporate Structure Context

Unitop Chemicals Private Limited operates as a material subsidiary of Rossari Biotech Limited, making this transaction significant enough to warrant disclosure under regulatory requirements. The parent company maintains its registered office at Rossari House, Golden Oak, LBS Marg, Surya Nagar, Vikhroli (West), Mumbai, with manufacturing facilities in Silvassa and Gujarat.